strategies to implement car-t in dlbcl
Published 2 years ago • 37 plays • Length 2:05Download video MP4
Download video MP3
Similar videos
-
5:43
strategies to overcome the current obstacles in car-t manufacturing
-
4:29
improving survival outcomes and optimizing car-t therapy in patients with dlbcl
-
6:54
the future of car-t therapy in the management of dlbcl
-
3:59
strategies to improve car t-cell manufacturing
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
46:57
methods to advance your car t & car nk cell research
-
5:02
automated car t cell manufacturing
-
2:21
car t-cell therapy: how does it work?
-
1:40
strategies to improve car-t outcomes in patients with lbcl
-
3:52
updates on the use of car-t therapy for the treatment of dlbcl in the second-line setting
-
5:24
treatment strategies for patients with dlbcl who relapse after car-t therapy
-
2:52
comparing the efficacy and curative potential of car-t therapy & bispecific antibodies in r/r dlbcl
-
1:31
strategies to minimize the occurrence of crs and icans in patients treated with car-t therapy
-
3:12
the role of car t-cell therapy in dlbcl
-
3:43
safety and efficacy of ytb323, a car t-cell therapy, in r/r dlbcl
-
2:21
car t-cell therapy: what clinicians need to know about managing the aes
-
7:40
immunotherapy for aml and all: checkpoint inhibitors & car t-cells for b-cell all
-
3:42
an overview of car-t therapy in dlbcl and mcl
-
3:55
managing relapse post-car-t therapy in dlbcl & the need to change clinical trial inclusion criteria
-
1:06
manufacturing strategies to improve car t-cell persistence
-
2:52
current immunotherapeutic approaches in dlbcl: the value of car-t cells and bispecific antibodies
-
2:06
improving our understanding of car-t therapy to avoid t-cell exhaustion